Pacira BioSciences, Inc.
Price Action
Technical Summary
EMERGING TRENDPacira BioSciences, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 58), indicating performance broadly in line with the market. Earnings contraction of 30% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $24.54 | -3.66% | BELOW |
| 50 SMA | $23.41 | +0.96% | ABOVE |
| 100 SMA | $23.24 | +1.72% | ABOVE |
| 150 SMA | $23.20 | +1.89% | ABOVE |
| 200 SMA | $23.67 | -0.14% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PCRX in an uptrend right now?
PCRX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is PCRX overbought or oversold?
PCRX's RSI (14) is 46. The stock is in neutral territory, neither overbought nor oversold.
Is PCRX outperforming the market?
PCRX has a Relative Strength (RS) Rating of 58 out of 99. PCRX is performing about average compared to the market.
Where is PCRX in its 52-week range?
PCRX is trading at $23.64, which is 86% of its 52-week high ($27.64) and 55% above its 52-week low ($18.80).
How volatile is PCRX?
PCRX has a Beta of 0.47 and 52-week volatility of 37%. It's less volatile than the S&P 500 - generally more stable.